KLOW is a four-ingredient peptide blend: GHK-Cu, BPC-157, TB-500 and KPV. It is marketed around recovery, skin quality and inflammation, but studies of the individual ingredients do not establish those benefits for the combined product. Its main difference from the GLOW formulation discussed on this site is the addition of KPV.
Adding KPV changes the formulation, not the certainty of its benefits. Check which material was tested, how it was delivered and whether the outcome was measured in people.
Product reference: See the KLOW 80 mg vial chart for the site’s concentration and measurement reference. Accurate arithmetic does not establish a clinically validated regimen.
What is in the KLOW peptide blend?
Pure Lab Peptides lists its KLOW 80 mg product as 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV. The listing identifies the TB-500 component as full-length, 43-amino-acid thymosin beta-4 and designates the product for laboratory research. This is product information, not a clinical trial. [1]
| Ingredient | KLOW 80 mg | GLOW 70 mg |
|---|---|---|
| GHK-Cu | 50 mg | 50 mg |
| BPC-157 | 10 mg | 10 mg |
| TB-500 | 10 mg | 10 mg |
| KPV | 10 mg | Not included |
| Total vial contents | 80 mg | 70 mg |
These are amounts in the whole vial, not amounts to administer. The GHK-Cu amount refers to the copper-peptide complex, not 50 mg of elemental copper. Check the actual label because blend names are not universal specifications. [1][2]
What does KPV add to the research?
KPV is a tripeptide made from lysine, proline and valine. In a 2008 study, researchers investigated how it entered intestinal epithelial and immune cells through a transporter called PepT1. It reduced inflammatory signaling involving NF-κB and MAP kinase in those laboratory experiments. [3]
The same paper studied KPV given in drinking water in two mouse models of colitis. Measures of intestinal inflammation improved. Although some experiments used human-derived cell lines, that does not mean people received KPV in the study.
This distinction matters for gut-health claims. Cells in a dish and mice with experimentally induced colitis cannot establish treatment effectiveness for a person with ulcerative colitis, Crohn’s disease, unexplained bloating or chronic abdominal pain. The study also did not test the four-component KLOW blend or an injected version of it. [3]
Are the claimed benefits of KLOW established?
Skin and collagen: GHK-Cu has skin-related research. One study examined collagen and elastin in cultured cells and evaluated a topical nano-carrier formulation in 40 women over eight weeks. That formulation improved measured wrinkle parameters. It was not a KLOW trial, and its results cannot establish the effect of an injectable blend. [4]
Injury recovery: BPC-157 research includes animal tendon-healing experiments. A rat Achilles-tendon study reported improved healing measures, but it did not establish recovery outcomes in people or test KLOW. A plausible tissue-repair mechanism is a reason to investigate, not a guarantee of faster recovery. [5]
Inflammation: KPV’s laboratory results are relevant to inflammatory pathways. They do not establish that the finished blend safely treats systemic inflammation. A claim this broad needs a defined condition and a measurable clinical outcome.
Fat loss: The studies cited here do not establish KLOW as a weight-loss treatment or show that it selectively reduces belly fat. Recovery and body-composition claims should not be bundled together as though they were the same endpoint.
Side effects and the safety gaps
There are no reliable blend-specific side-effect rates in the evidence reviewed here. In its May 2026 KPV evaluation prepared for the July advisory meeting, FDA reported that it had not identified clinical studies or human exposure data for KPV by any route. The document also described gaps in information about immune reactions and peptide aggregation. That is a dated evidence assessment, not proof that adverse effects cannot occur. [6]
For a multi-ingredient product, the unanswered questions also include interactions, stability and which component could cause a reaction. A laboratory purity result does not answer all of them.
Do not replace care for an injury or inflammatory condition with a research blend. Discuss any proposed product with a qualified clinician, including your medicines, pregnancy or breastfeeding status and relevant medical conditions. A list of ingredients alone cannot determine whether a combination is appropriate for you.
How long does KLOW take to work?
A reliable timeline has not been established for this blend. Neither a mouse colitis experiment nor an eight-week topical GHK-Cu study establishes when KLOW should produce a noticeable effect, how long that effect would last or an appropriate cycle length.
Anecdotes can describe what someone noticed, but changes in training, rehabilitation, skin care, sleep and other treatments can occur at the same time. “I felt better after starting it” and “the blend caused the improvement” are different claims.
Common questions
Is KLOW better than GLOW?
There is no head-to-head clinical comparison in the sources reviewed here. KLOW adds KPV to the specified GLOW combination; an additional ingredient does not prove an additional benefit. Our GLOW guide explains the three-ingredient blend separately.
Is a KLOW blend the same as a peptide stack?
A blend generally means ingredients combined in one formulation. A stack can mean separate products used together. Neither term establishes compatibility or clinical evidence. Separate containers also do not make a combination tested or safe.
Is there a standard KLOW dosage?
The cited research does not establish a universal human regimen for the finished blend. The vial total, concentration and amount in a measured volume are different quantities. A measurement chart should not be mistaken for a validated treatment schedule.
Does a compounding discussion mean KLOW is FDA-approved?
No. An ingredient’s consideration for compounding is different from approval of a finished medicine. FDA states that compounded drugs are not FDA-approved and do not undergo the same premarket verification of safety, effectiveness and quality. [7]
The formulation described here has a stated ingredient list, but its human benefits remain uncertain. Studies need to match the formulation and route; findings about four separate ingredients don’t demonstrate a combined effect.
References
- Pure Lab Peptides. KLOW 80 mg product listing. Composition and product identity only.
- Pure Lab Peptides. GLOW 70 mg product listing. Composition comparison only.
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.
- Badenhorst T, et al. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. Journal of Aging Science. 2016.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003.
- FDA. Evaluation of KPV-related bulk drug substances. May 12, 2026; briefing for the July 2026 Pharmacy Compounding Advisory Committee meeting.
- FDA. Compounding and the FDA: questions and answers.